Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse
This study has been completed.
Sponsor:
Palo Alto Medical Foundation
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002064
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: June 1989
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii.
| Condition | Intervention |
|---|---|
|
Toxoplasmosis, Cerebral HIV Infections |
Drug: Pyrimethamine Drug: Clindamycin |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
| Official Title: | Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse |
Resource links provided by NLM:
Genetics Home Reference related topics:
complement factor I deficiency
Drug Information available for:
Pyrimethamine
Clindamycin hydrochloride
Clindamycin phosphate
Clindamycin palmitate hydrochloride
Clindamycin palmitate
U.S. FDA Resources
Further study details as provided by NIH AIDS Clinical Trials Information Service:
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions are excluded:
- Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal meningitis) or other conditions (brain abscess) which would make treatment results difficult to interpret due to concurrent infection, disease, or therapy.
Patients with other opportunistic infections or brain diseases are excluded.
Patients with AIDS and cerebral toxoplasmosis.
Contacts and Locations
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00002064 History of Changes |
| Other Study ID Numbers: | 021A |
| Study First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by NIH AIDS Clinical Trials Information Service:
|
Sulfonamides Toxoplasmosis AIDS-Related Opportunistic Infections Pyrimethamine |
Drug Therapy, Combination Encephalitis Acquired Immunodeficiency Syndrome Clindamycin |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Encephalitis Toxoplasmosis Toxoplasmosis, Cerebral Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Central Nervous System Viral Diseases |
Brain Diseases Central Nervous System Diseases Nervous System Diseases Central Nervous System Infections Coccidiosis Protozoan Infections Parasitic Diseases Brain Abscess Abscess Suppuration Infection Central Nervous System Protozoal Infections Central Nervous System Parasitic Infections Clindamycin Clindamycin-2-phosphate |
ClinicalTrials.gov processed this record on May 21, 2013